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Abstract 
More than 100 countries around the world currently require or permit 
International Financial Reporting Standards (IFRS) reporting in 2009. When U.S. 
companies convert from U.S.Generally Accepted Accounting Principles (U.S. GAAP) 
to IFRS, they are faced with great challenges as well as opportunities to make choices 
on financial reporting policies. A survey of leading European pharmaceutical 
companies that used U.S. GAAP prior to the IFRS adoption was conducted to 
evaluate their first-time adoption of IFRS practices. The survey results are structured 
into three aspects and discussed in this thesis. First, IFRS 1 optional exemptions at 
transition date. Second, key accounting differences from IFRS to U.S. GAAP 
reconciliation, and the third, choices of alternative accounting methods allowed by 
IFRS. U.S. pharmaceutical companies can learn from these results to choose IFRS 1 
optional exemptions to their best interest, to prepare reconciliation between U.S. 
GAAP and IFRS and to make accounting choices under IFRS for their first time 
adoption of IFRS. These results not only provide benchmark information, but also 
provide U.S. companies a cost-effective pathway in making their reporting choices in 
the near future when U.S. companies convert from U.S. GAAP to IFRS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
For the past several years, there has been strong momentum building toward using 
a set of high quality global accounting standards that could be applied by companies 
and understood by investors around the world. Currently, more than 100 countries 
around the world have adopted International Financial Reporting Standards (IFRS) 
reporting (Tsakumis, Campbell, & Doupnik, 2009). Approximately 85 of those 
countries require IFRS reporting for all domestic and listed companies, including 
Germany, France, Italy, and England. More and more global players will sooner or 
later convert to IFRS, including Japan and Canada (Mirza, Orrell & Holt, 2008). The 
IFRS conversion is more than just a technical accounting practice. It could have a 
significant impact on accounting policies, internal controls, financial reporting and 
disclosure and related parties (Thomas, 2003). 
United States Securities and Exchange Commission (SEC) has made 
groundbreaking movement regarding IFRS. It made an announcement on November 
15, 2007 to allow foreign private issuers to enter the US capital market using IFRS 
financial statements. This was considered a historical move. For the existing foreign 
registrants, they do not need to provide a reconciliation to be based on U.S. Generally 
Accepted Accounting Principles (U.S. GAAP) if accepted international accounting 
standard such as IFRS is used (SEC. 2007). The SEC released a long-awaited road 
map indicating the course of action for U.S. public companies converting to IFRS. 
The SEC proposed Roadmap is set forth as such: proposed voluntary application of 
IFRS will be permitted for some U.S. registrants at fiscal years ending after December 
15, 2009. During 2011, the SEC will reconvene to decide whether a mandatory 
conversion date should be set. Proposed roadmap requires all U.S. public companies 
to report financial statements using IFRS in 2014 (SEC, 2008). Considering this 
financial crisis now, the SEC acknowledges that the pace for roadmap is slowing 
down (Forgeas, 2009). However, “SEC chief accountant James Kroeker said the 
roadmap would be an important priority this fall”, and we can expect to hear more 
about IFRS from Commission (AICPA, 2009). 
  Many publicly traded European Union (EU) companies used U.S. GAAP to 
prepare their consolidated financial statements for various strategic reasons prior to 
the IFRS mandate . Majority of European pharmaceutical companies such as 
AstraZeneca, Glaxosmithkline, Merck, Novarits, Novo Nordisks, Roche, 
Sanofi-Aventis and Schering have already adopted IFRS since 2005 or even earlier 
(Ernst &Young, 2006). When U.S. companies convert from U.S. GAAP to IFRS, they 
will be faced with great challenges as well as chances in making choices on financial 
reporting policies. U.S. pharmaceutical companies can benefit from these European 
companies by learning how they applied the guidance provided in IFRS 1 and 
selected new IFRS accounting policies as they begin to prepare for their first IFRS 
financial statements. By using IFRS, companies can reduce reporting costs, have 
greater access to world capital markets, and increase their ability to move accounting 
personnel around countries (AICPA, 2009). However, the disadvantage of converting 
to IFRS faced by all U.S. companies is the conversion cost. In November 2008, SEC 
provided an estimate of $32 million for the conversion cost for companies that would 
qualify for the early transition in 2009 (Forgeas, 2009). The pharmaceutical industry, 
compared to other industries, faces many challenges in converting to IFRS and needs 
more attention because its uniqueness in each of the following areas: revenue 
recognition, development costs, and intangible assets (Ernst & Young, 2006).  
This study surveys the transition reporting practices and accounting choices 
adopted by eight leading European Union pharmaceutical companies, which are 
cross-listed in the U.S. and have successfully switched to IFRS from U.S. GAAP. 
Their experience with conversion to IFRS from U.S. GAAP is valuable for U.S. 
issuers because they are equivalent to U.S. issuers to the extent that they had used U.S. 
GAAP for their consolidated financial statements until 2007. The research tools 
include SEC EDGAR Company Search, Business Database: Financial Markets and 
Services and Net Advantage. 
The survey results of these pharmaceutical companies are structured into three 
sections: 
 (1) IFRS 1 optional exemptions 
  (2) Key differences between IFRS and U.S. GAAP reconciliation 
 (3) Choices of alternative accounting methods allowed by IFRS. 
 (4) Important accounting policies 
In addition to the four sections above, this thesis also includes a discussion of 
determinants of accounting choices and an appendix. 
Table 1 is a list of surveyed pharmaceutical companies which adopted IFRS in 
preparing their annual report and had used U.S. GAAP before converting to IFRS. 
These companies can thus provide direct comparison between IFRS and U.S. GAAP. 
［Insert Table 1 here］ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. IFRS 1 Optional Exemptions 
The International Accounting Standards Board (IASB) published IFRS 1, 
First-time Adoption of International Financial Reporting Standards. IFRS 1 
established the transition requirements for the first-time adopter to prepare the 
financial statements under IFRS. It requires a first-time adopter to apply IFRS at the 
reporting date retrospectively. Thus, these companies are presented as if they had 
always used IFRS for financial reporting. IFRS 1 contains mandatory exemptions to 
retrospective application in certain areas. IFRS 1 also provides optional exemptions to 
the general restatement in certain areas in which retrospective application is difficult 
or costs would exceed the benefits to the users of financial statements, areas such as 
business combination and cumulative translation difference. The purpose of these 
optional exemptions is to ease the burden of first-time adoption of IFRS (Deloitte, 
2004). Table 2 below summarizes optional exemptions provided by IFRS 1. 
［Insert Table 2 here］ 
 
Summary of Elected Optional Exemptions 
Consistent with Hwang and Lin (2009), I focus on the four most commonly used 
optional exemptions, which are presented in Table 3. In the following discussion, I 
first list the rule of exemption option provided under IFRS 1 in applying a particular 
standard (The option II refers to the full retrospective restatement of an IFRS 
standard). I then report survey results and relevant excerpts as to how companies 
apply an exemption so US companies can learn to prepare such discussions. 
GPC Biotech converted to IFRS from U.S. GAAP in the year of 2005 but did not 
provide IFRS financial statements until 2007, in which it did not provide first time 
adoption practices. Thus it is excluded from the discussion of optional exemptions but 
kept for other parts of this thesis. Table 3 below summarizes the most commonly used 
optional exemptions by the seven pharmaceutical companies. 
［Insert Table 3 here］ 
 1.1 Item 1: IFRS 3R Business combinations  
For transactions qualifying as business combinations under IFRS 3, an entity can 
choose to: 
I. Not restate business combinations before the date of transition, (i.e. full 
exemption applied) 
II. Restate all business combinations before the date of transition, (i.e., 
retrospective application) 
III. Restate all business combinations starting from a date it select prior to the date 
of transition. (i.e., partial exemption applied)  
In all cases, the entity must apply IAS 36 impairment guidance to any remaining 
goodwill in the opening IFRS balance sheet, after reclassifying, as appropriate, 
previous GAAP intangibles to goodwill.  
Survey Results for Item 1 
Elan, Shire, MediGene, World of Medicine and Schwarz applied option I by not 
restating business combinations before the date of transition. Evotec and Sygnis did 
not take and discuss this option in their annual reports. In conclusion, Five out of 
seven pharmaceutical companies applied option I by not restating business 
combinations before the date of transition. This approach must have saved these 
companies money and effort. Basically, it can be concluded that it is in the company’s 
best interest not to restate any business combination that occurred before the transition 
date. 
 
Excerpts from option I adopters: 
Elan–from 2005 Annual Report page156 
“Business combinations undertaken prior to the transition date of 1 January 2004 
have not been subject to restatement and accordingly, goodwill at the transition date 
is carried forward at its net book value and is subject to annual impairment testing in 
accordance with IAS 36, ‘‘Impairment of Assets.””  
Shire–from 2005 Annual Report page102 
 “The Group has applied the business combination exemption in IFRS 1. It has not 
restated business combinations that took place prior to the January 1, 2004 transition 
date in accordance with IFRS 3, “Business Combinations””. 
MediGene–from 2005 Annual Report page55 
The previous accounting principles for corporate mergers carried out before the 
transition date (January 1, 2004) would not be adapted to the new principles. 
World of Medicine–from 2005 Annual Report page37 
“Business combinations accounted for prior to the period of transition to IFRS, prior 
to January 1, 2004, were not retroactively adjusted to IFRS 3”. 
Schwarz–from 2005 Annual Report page39 
The following exemptions from retrospective adjustment were elected pursuant to 
IFRS 1: 
“Business combinations (IFRS 1.15): Goodwill from historic acquisitions of 
companies measured and carried forward under US GAAP is carried forward in the 
opening balance sheet. The balance sheet values as per 1 January 2004 were tested 
for impairment pursuant to IAS 36”. 
 
1.2 Item 3: IAS 19 Employee benefits on actuarial gains and losses  
An entity may elect to:   
I. Recognize all cumulative actuarial gains and losses for all defined benefit plans as 
an adjustment to opening retained earnings, even if it elects to use the IAS 19 
corridor approach for actuarial gains and losses that arise after first-time adoption 
of IFRS. That is, an entity may reset any corridor recognized under previous GAAP 
to zero. 
II. Restate all defined benefit plans under IAS 19 since the inception of those plans 
and defer the restated cumulative actuarial gains and losses.  
Survey Results for Item 3 
Schwarz, Elan and MediGene applied option I by recognizing cumulative 
actuarial gains and losses as an adjustment to opening retained earnings. Evotec, 
 Sygnis and Shire did not apply this option since they have used defined contribution 
plan. World of Medicine did not take this option and did not discuss this item. In 
conclusion, for item 3, no obvious pattern has been observed here since three 
companies have used defined contribution plan. However, three out of the rest four 
companies selected option I. Even though MediGene’s discussion is not very clear, it 
doesn’t affect the conclusion that selecting option I serve these companies best. 
 
Excerpts from option I adopters: 
Schwarz–from 2005 Annual Report page39 
“Employee benefits (IFRS 1.20): All actuarial gains and losses exceeding the 10% 
corridor of the higher value of the present value of the pension liabilities and the plan 
assets as per 1 January 2004 were fully set off against employee benefits, leaving no 
actuarial gains and losses unrecognized in shareholders’ equity.  P118: As 
mentioned above, the SCHWARZ PHARMA Group has opted to use the exemption 
provisions under IFRS 1 as regards pensions and has set off all unrealized actuarial 
gains and losses against pension provisions (Employee benefits)”. 
Elan –from 2005 Annual Report page156 
“Employee benefits: The corridor method has been applied retrospectively and the 
cumulative actuarial gains and losses from the date of inception of our defined benefit 
pension plans have been split into a recognized portion and an unrecognized portion 
and the recognized portion has been adjusted against retained loss in the opening 
balance sheet”. 
MediGene–from 2005 Annual Report page63 
“As at December 31, 2004, no actuarial gains or losses were reported due to the use 
made of the relief option in accordance with IFRS 1. Actuarial gains and losses 
arising from experience adjustment and changes in actuarial assumption are posted 
to income over the employees expected average remaining working lives”. 
 
1.3 Item 4: IAS 21 Cumulative (foreign) translation differences 
An entity may elect to: 
 I. Recognize all translation adjustments arising on the translation of the financial 
statements of foreign entities in accumulated profits or losses at the opening IFRS 
balance sheet date. Similar to the effect of Item 3 discussed previously, an entity may 
elect to reset the translation reserve included in equity under previous GAAP to zero. 
If the entity elects this exemption, the gain or loss on subsequent disposal of the 
foreign entity will be adjusted only by those accumulated translation adjustments 
arising after the opening IFRS balance sheet date.  
II. Restate the translation reserve for all foreign entities since they were acquired or 
created. 
Survey Results for Item 4 
 Shire, MediGene, and Sygnis chose this exemption: the cumulative translation 
reserve reset to zero. The other four companies did not take this option. There is no 
obvious pattern observed for this item. Given the fact observed from Table 4, these 
non-option I adopters have been experiencing big losses on this item for several years 
in a row, I boldly surmise that since 2004, the first year in which companies started to 
convert to IFRS, companies, without relative experience to rely on, inevitably acted 
conservatively. 
Excerpts from option I adopters: 
Shire–from 2005 Annual Report page102 
“The Group has elected to set the previously accumulated cumulative translation 
differences arising on the translation and consolidation of results of foreign 
operations and balance sheets denominated in foreign currencies to zero at January 1, 
2004. This exemption has been applied to all subsidiaries in accordance with IFRS 
1”. 
MediGene–from 2005 Annual Report page55 
“IFRS 1 allows companies to apply the standard IAS 21 (the effects of changes in 
Foreign Exchange rates) prospectively. This means that it is assumed that all of the 
accumulated currency exchange gains and losses reported according to US-GAAP 
before the transition date are valued at zero as at the date of transition to IFRS. And 
 that currency exchange differences which arise after the transition date must be 
reported separately in the balance sheet for each foreign subsidiary. The differences 
that emerge are set at zero at the date of transition”. 
Sygnis–from 2005 Annual Report page32 
“The company used the option of IFRS 1.22, which allows the accumulated foreign 
currency exchange differences from foreign operations to be set at zero in the opening 
balance sheet”.  
Discussions for non-option I adopters: 
Elan 
Elan did not take option I for this item because U.S. dollars is the functional 
currency for the parent company and the majority of the group companies. Below is 
an excerpt regarding this item taken from Elan 2005 IFRS annual report page80: 
“Financial Statements are presented in U.S. dollars rounded to the nearest 
million, being the functional currency of the parent company and the majority of 
the group companies”. 
Even though in 2005 Elan IFRS Annual Report (page74), in stockholders’ equity, 
this item is a big loss (-$15.6 million). However, there is a decreasing pattern in this 
item from 2005 to 2008; they are -$15.6 million, -$11.7 million, -$11.0 million, and 
-$11.0 million respectively. 
Evotec 
Through reading financial reports from 2004 to 2008, I found the cumulative 
foreign currency translation item for 2005 to be € –35,856,000, which is carried over 
and this loss is getting bigger.  
Schwarz 
Schwarz also did not take option I. However, it is interesting to see that during 
2005, this item is decreased dramatically from €-61,829,000 to €-861,000. The exhibit 
below is taken from Schwarz 2005 Annual Report to show this dramatic change.  
［Insert Exhibit 1 here］ 
 
 World of Medicine 
No pattern is observed for this item through financial statements from 2004 to 
2008. Table 4 summarizes the cumulative translation differences from non-option I 
adopters.  
［Insert Table 4 here］ 
 
1.4 Item 8: IFRS 2 Share-based payment transactions 
An entity may choose:  
I-1. Not to apply IFRS 2 to any equity instruments those were granted before 
November 7, 2002. 
I-2. Not to apply IFRS 2 to any equity instruments that were granted after November 
7, 2002 and vested before the date of transition, but only if the company has 
previously disclosed publicly the fair value of the instruments, determined at the 
measurement date. 
II. To apply IFRS 2 to a liability relating to a cash-settled share-based payment that 
was settled prior to the date of transition to IFRS. 
Survey Results for Item 8 
Sygnis and World of Medicine did not provide such discussions. All other 
companies have chosen the option I, which is not to apply IFRS 2 to any equity 
instruments that were granted before November 7, 2002, or that were granted after 
that date and vested before the date of transition. In conclusion, except that two 
companies did not provide such discussions, the rest of five companies selected 
option 1. Thus it is safe to say that option I serves these companies the best. 
Excerpts from option I adopters: 
Evotec–from 2005 Annual Report page69 
“IFRS 2, only stock options, which were granted after 7 November and not vested on 
31 December 2005, are included in the fair value calculation”. 
Elan–from 2005 annual report page156 
“Share-based payments: IFRS 2 has been applied retrospectively to those options that 
 were issued after 7 November 2002 and had not vested by 1 January 2005”. 
Schwarz–from 2005 Annual Report page39 
“Stock option programs prior to 7 November 2002 and those granted after 7 
November 2002 that were already fully exercisable at the time of the opening balance 
sheet, were not taken into consideration in preparing the opening balance sheet”. 
MediGene–from 2005 Annual Report page55 
“The reporting of share-based instruments that were issued before November 7, 2002 
is waived”. 
Shire–from 2005 Annual Report page102 
“The Group has elected to apply the share-based payment exemption. It applied IFRS 
2 from January 1, 2004 to those options that were issued after November 7, 2002 but 
that have not vested by January 1, 2005”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2. Reconciliation of Key Accounting Differences  
IFRS 1 also requires that the first IFRS financial statements include a reconciliation 
of:  
(1) Equity from U.S. GAAP to IFRS at the transition date and at the end of the latest 
period presented in the company’s most recent annual financial statements under U.S. 
GAAP; 
(2) Net profit from U.S. GAAP to IFRS for the last period in the company’s most 
recent annual financial statements under U.S. GAAP.  
The reconciliation information required by IFRS 1 and included in a 
reconciliation table usually indicates how equity and net profit from U.S. GAAP get 
reconciled to IFRS. The reconciliation disclosures from the eight companies are 
summarized in Tables 5 to 8. Specific items in reconciliation disclosures are listed in 
an attempt to find what the key items are. A summary of major items in reconciliation 
disclosures from the eight companies and the effects of IFRS transition on financial 
ratios are also included in Table 9 and Table 10 in this section.  
I found that IFRS adoption results in lower net income and higher shareholders’ 
equity than U.S. GAAP for our sampled companies. The mean (median) differences 
between U.S. GAAP and IFRS net income and shareholders’ equity are -59.34% and 
15.07% respectively (-0.63% and 3.65% respectively). Elaine, Lin, and Yang (2008) 
used 75 European companies cross-listed in the U.S., but found that IFRS provided 
higher (lower) net income (shareholders’ equity) than U.S. GAAP. They find that the 
mean (median) accounting differences between U.S. GAAP and IFRS net income and 
shareholders’ equity are 2.11% and -11.64%, respectively (1.40% and -1.18%). I used 
the same calculation method, but my results were quite different from theirs. It 
probably could be attributed to following facts: 1. Small sample size. 2. Different 
transition date (2004) 3. Seven out of eight companies are experiencing big losses, 
which could have something to do with the lower net income under IFRS. In these 
IFRS financial statements, I did not observe any obvious national identities, as Ernst 
&Young (2006) mentioned that IFRS financial statements retain their national identity. 
 This is probably because the majority of the companies are from Germany and 
because all these sampled companies unanimously used U.S. GAAP before 
converting to IFRS. Table 5 below presents net incomes of eight companies under 
both U.S.GAAP and IFRS 
［Insert Table 5 here］ 
  
Table 6 summarizes specific items and their proportions to the IFRS Net Income in 
reconciliation table. No obvious pattern was observed from the following tables and 
these specific items and their proportion vary significantly from company to company 
even though they belong to the same industry.  
［Insert Table 6 here］ 
Table 7 presents stockholders’ equities of eight companies under both U.S. GAAP and 
IFRS. 
［Insert Table 7 here］ 
 
Table 8 summarizes specific items and their proportions to IFRS Stockholders’ Equity 
(SE) in the Reconciliation Table. No obvious pattern was observed from the following 
tables and these specific items and their proportions vary significantly from company 
to company even though they belong to the same industry. 
［Insert Table 8 here］ 
Here I have summarized the relatively major items in the reconciliation 
disclosures of these companies in Table 9 and have included excerpts on these items. 
［Insert Table 9 here］ 
 
Elan 
Excerpts from 2005 Elan IFRS Annual Report page153 
Financial instrument-We have adopted IAS 32 and IAS 39 effective 1 January 2005, 
which eliminates many of the investment related differences with our U.S. GAAP 
results. The principal remaining differences from 2005 onwards relate to the different 
carrying values for some of our investments under IFRS as compared to U.S GAAP. 
 The definition of a derivative instrument under U.S. GAAP is similar to the IFRS 
definition with the result that the number of derivatives recorded at fair value through 
the income statement will be similar for both GAAPs. However, under U.S. GAAP, 
certain non-derivative investments, principally equity investments in private entities, 
are not marked-to-market through the balance sheet, whereas all non-derivative 
investments are marked-to-market through the balance sheet under IFRS with fair 
value changes taken through the fair value reserve. 
Revenue recognition-There are different rules under IFRS and U.S. GAAP in relation 
to the recognition of revenue arising under contracts which include multiple 
arrangements such as the sale of a product and related R&D or manufacturing 
arrangements, although the revenue recognized will be the same under both IFRS and 
U.S. GAAP over the life of the contract, the different requirements can result in 
differences in the timing of revenue recognition.  
 
Schwarz  
Under U.S. GAAP, Schwarz used average and LIFO method for inventory valuation. 
Under IFRS, only average method was used since LIFO is prohibited by IFRS, which 
is the primary cause of the reconciliation differences in the inventory accounts. 
Excerpt–from 2005 Schwarz Annual Report page40 
Under U.S. GAAP, Inventories are stated at the lower of cost or market. Cost is 
generally determined in accordance with the average cost method. Certain foreign 
companies determine cost using the last-in, first-out method. 
Employee benefits-As mentioned above, the SCHWARZ PHARMA Group has opted to 
use the exemption provisions under IFRS 1 as regards pensions and has set off all 
unrealized actuarial gains and losses against pension provisions (Employee benefits). 
 
Evotec 
Excerpts from Evotec 2005 IFRS Annual Report page60 
Impairment (goodwill) – under U.S. GAAP impairment is determined by comparing 
the value of the cash generating unit (reporting unit) to which goodwill is attributed 
 using after tax cash flows discounted at an after tax discount rate, to the fair value of 
the assets of that reporting unit. Under IFRS no fair value adjustments are made and 
pre-tax cash flows and pre-tax discount rates are used. 
Impairment (property, plant and equipment) – under U.S. GAAP, where there is an 
indication of an impairment of a fixed asset, the impairment is calculated by 
determining the value of the asset to the business using non-discounted cash flows 
and comparing this to the carrying value. Under IFRS a similar method to that of 
goodwill impairment is used. Asset impairments under IFRS may be reversed if 
conditions change. 
 
Sygnis  
Sygnis sold its core business, bioinformatics unit in 2005. Adjustment of 
severance provision is the only item in the reconciliation table.  
Excerpts from Sygnis 2005 Annual Report page31: 
Adjustment of severance-Under US-GAAP, severance provision for employees are 
accounted for on a pro-rata basis if the term between the termination and the actual 
ending of the employment is longer than usual (normally more than three months), 
under IFRS such a liability is immediately accounted for at the total amount. This 
effect reduced equity in the opening balance as of April, 2004 by € 260 thousand, 
which was however counterbalanced by the counter effect in fiscal year 2005, 
however, the same issue resulted in a reduction of equity of € 55 thousand as of March 
31, 2005. 
 
World of Medicine  
Excerpts from World of Medicine 2005 Annual Report page57 
Deferred tax adjustment-IFRS and USGP differ from each other regarding the 
accounting of deferred taxes in that, according to IFRS, deferred taxes are always 
shown as non-current balance sheet items. 
The changes to balance sheet items between IFRS and USGP in the opening balance 
that led to a €179 difference in shareholder equity primarily due to the adjustment of 
 budget horizon for the calculation of tax deferrals to losses carried forward. 
 
The effects of IFRS transition on financial ratios 
The key financial ratios under both U.S. GAAP and IFRS from four companies are 
compared and summarized in Table 10 in an attempt to have better understanding on 
the effects of IFRS transition on financial ratios. These financial ratios are 
representative of important aspects of financial status which include liquidity, 
profitability, activity, and financial leverage. Table 10 below summarizes the effects of 
IFRS transition on financial ratios 
［Insert Table 10 here］ 
 
For liquidity ratios, the current ratio is theoretically increased after IFRS 
transition because deferred income tax is removed from current liabilities. This result 
was observed in the results, but I did not discuss deferred income tax here since this 
complex item is subject to regulations of the nations in which the companies operate. 
For profitability ratio, the return on assets should theoretically vary with the 
changes on net incomes and assets. The results show that the ratios unanimously 
become higher. This could be due to small size or coincidence. 
For activity ratio, asset turnover is theoretically lower because sales are usually 
the same and assets increase after IFRS transition. The results show that ratios of 
three companies become lower and only one ratio becomes higher 
For leverage ratio, it should theoretically be lower (higher) as net income 
becomes higher (lower) after IFRS transition. The results here do not show this 
correlation, but show that the ratios unanimously become lower. Again, it could be 
due to small sample size.  
 3. Accounting Choices 
The first-time adoption of IFRS also presents companies opportunity to change and 
reevaluate their accounting policies. IFRS allows companies to choose from a number of 
alternative accounting treatments—for example, the reclassification of interest income 
into operating activity or investing activity etc. Table 11 below summarizes the 
accounting choices provided by IFRS and the choices made by the surveyed 
pharmaceutical companies. A discussion follows Table 11.  
［Insert Table 11 here］ 
Discussion for accounting choices 
IAS 1, Presentation of Financial Statements, provides two options to classify 
expenses under Income Statement by function or by nature. All companies classify 
expenses by function as reported under U.S. GAAP.  
IAS 7, Cash Flow Statement, permits either indirect or direct methods to prepare the 
statement. The indirect method has been uniformly applied by all of the companies. IAS 
7 also allows optional choices on the activity classification for the interest expense, 
interest income, and dividend income in operating, investing, or financing activities.  
IAS 2, Valuation of Inventories, allows two methods: FIFO or average. Because 
inventory is not material to GPC Biotech, there is no discussion about this item. There is 
also no discussion on this item for MediGene and Sygnis. Evotec and World of Medicine 
have followed their previous U.S. GAAP practices by using the average method. 
Schwarz was the only company that used LIFO and average under U.S. GAAP and 
selected only the average method for IFRS reporting. 
IAS 16, Property, Plant and Equipment, allows for either revaluation or cost 
valuation methods. None of these companies chose the revaluation method based on the 
fair value model. Like U.S. GAAP, IFRS also allows choices for depreciation methods. 
All firms have uniformly chosen the straight line method.  
IAS 19, Employee Benefits (on actuarial gains/losses), permits immediate 
recognition of actuarial gains/losses to equity or the corridor method, which is 
commonly used under U.S. GAAP. Elan and Schwarz have followed their previous U.S. 
 GAAP practices by using the corridor method. GPC Biotech, Evotec and Shire used the 
defined contribution plan. MediGene chose the immediate recognition approach. Sygnis 
and World of Medicine did not provide such discussions.  
I also surveyed how firms apply the exchange rates per IAS 21, The Effects of 
Changes in Foreign Exchange Rates, to measure various financial statements. Except 
GPC Biotech, which used spot rate of transaction date for its income statement, all of the 
other surveyed companies reported period-end rates for their balance sheet and average 
rates for their income statement. None of the eight companies disclosed the use of 
exchange rates for their statements of cash flow. 
Finally, I surveyed the option pricing model used for IFRS 2, Share-Based 
Payments/Stock Options. Except for MediGene which used the binomial model, all other 
companies used Black-Scholes option-pricing model. An excerpt for this item is presented 
below to explain why MediGene chose to use the binomial model. 
Excerpt -- from MediGene 2005 Annual Report page62: 
The fair values of the options that MediGene grants in return for employees work 
performance are reported as expenses. The instruments are valued with the help of the 
binomial model instead of the Black Scholes method that was used in the previous years. 
The latter can not be used under IFRS because it doesn't portray the fair value correctly. 
The binomial model takes account of, among other things, vesting periods, hurdle rate, 
volatility of the underlying value and interest rates. 
 
 
 
 
 
 
 
 
 
 
 
 
 4. Important Accounting Policies 
Since the pharmaceutical industry differs from other industries in the areas of 
research and development (R&D) and revenue recognition, I have analyzed these two 
areas separately.  
4.1 Revenue recognition 
Under IFRS, rules for revenue recognition are more general compared with those 
under U.S. GAAP. According to IAS 11, in general, revenues are recognized when it is 
probable that the company will receive economic benefit and the amount of revenue can 
be reliably determined. In addition, the main risks and opportunities connected with the 
ownership of sold products must have been transferred to the buyer. Table 12 below 
presents revenue figures of seven companies from both U.S. GAAP and IFRS  
［Insert Table 12 here］ 
Elan and GPC Biotech are the only two companies that have different revenue figures 
under U.S. GAAP and IFRS. Excerpts on revenue are taken from their annual reports to 
explain why their revenue figures are different under U.S. GAAP and IFRS. 
Excerpts on revenue from Elan and GPC Biotech: 
Elan –from 2005 IFRS Annual report page154 
There are different rules under IFRS and USGP in relation to the recognition of revenue 
arising under contracts which include multiple arrangements such as the sale of a 
product and related R&D or manufacturing arrangements, although the revenue 
recognized will be the same under both IFRS and USGP over the life of the contract, the 
different requirements can result in differences in the timing of revenue recognition.  
GPC Biotech: the only difference in revenue description between IFRS and U.S. GAAP 
is grant revenue. 
Excerpt from 2007 IFRS Annual report Page48: 
Grants from governmental agencies for the support of specific research and development 
projects are recorded as other income to the extent the related expenses have been 
incurred and billed in accordance with the terms of the grant.  
 
 4.2 Research and development (R&D) cost 
Development costs are capitalized as an intangible asset if all of the following criteria 
are met [IAS 38R.57]: 
a) The technical feasibility of completing the asset so that it will be available for use or 
sale; 
b) The intention to complete the asset and use or sell it; 
c) The ability to use or sell the asset; 
d) The asset will generate probable future economic benefits and demonstrate the 
existence of a market or the usefulness of the asset if it is to be used internally; 
e) The availability of adequate technical, financial and other resources to complete the 
development and to use or sell it; and 
f) The ability to measure reliably the expenditure attributable to the intangible asset. 
For this R&D part, I have summarized accounting treatments for R&D expenditures 
from PWC and KPMG publications. I also have summarized the accounting difference in 
R&D and intangible assets from U.S. GAAP to IFRS for these pharmaceutical companies. 
Below is a summary of accounting treatments for R&D expenditures from PWC and 
KPMG publications.  
 
 U.S.GAAP IFRS 
Similarity Research costs are expensed as incurred under both accounting models. 
Difference 
With very limited exceptions, US 
GAAP prohibits the capitalization of 
development costs. 
In the area of software development 
costs, US GAAP provides different 
guidance depending on whether the 
software is for internal use or for sale. 
 
 
The recognition and measurement of 
intangible assets could differ significantly 
under IFRS. 
Development costs under IFRS are 
capitalized if certain criteria are met. In the 
area of software development costs, The 
principles surrounding capitalization under 
IFRS, by comparison, are the same whether 
the internally generated intangible is being 
developed for internal use or for sale. 
   
Table 13 below presents accounting difference in R&D and intangible asset from U.S. 
GAAP to IFRS. After 1/1/2004, all companies have expensed development costs as 
 incurred, except Evotec which met the criteria and capitalized as intangible asset. Most 
companies have not capitalized development costs since IFRS took effect in 2005. After 
converting to IFRS, R&D tends to decrease the mean and median by -3% and -0.3% 
respectively while intangible assets tend to increase the mean and median by 25% and 6% 
respectively. 
［Insert Table 13 here］ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5. A Brief Discussion of Agency Theory in Explaining Accounting Choices 
The choice made at the first time adoption of IFRS can have a significant impact on 
financial statements and strategy implications. Companies can benefit from a fresh start 
by choosing optional exemptions (Cormier, Demaria, Lapointe-Antunes & Teller, 2008). 
Cazavan-Jeny & Jeanjean (2007), in their paper, examine the determinants of 
management choices regarding IFRS transition. According to Cazavan-Jeny & Jeanjean 
(2007), the impact of a transition to IFRS on key items is relatively limited due to the 
companies’ accounting policies. The difference between national GAAP and IFRS usually 
comes from mandatory adjustments and optional exemptions. The optional exemptions 
allowed by IFRS 1 enable firms to offset the impact of mandatory adjustments required 
by IFRS 1 (Cazavan-Jeny & Jeanjean, 2007). Their results are very interesting as they 
show that companies are making accounting policy choices that can be considered 
opportunistic while financial reporting is supposed to be more transparent. Managers pay 
attention to the published figures because those figures can affect their bonus and the 
firm’s competitive position.  
Their research hypotheses are formulated based on agency theories and signaling 
theories, which have significant impacts on accounting choices. The hypotheses are that 
optional exemptions are used to minimize the effect of mandatory adjustments on equity 
and that Firms choose the options that will enable them to reduce their apparent leverage 
(Cazavan-Jeny & Jeanjean, 2007).  
 
 
 
 
 
 
 
 
 
 
 
 6. Conclusion 
It has been a growing trend to use a set of high quality global accounting standards 
that could be applied by companies and understood by investors around the world. Today, 
more than 100 countries around the world require or permit IFRS reporting. Proposed 
voluntary application of IFRS will be permitted for some U.S. registrants at fiscal years 
ending after December 15, 2009 according to SEC’s proposed roadmap.  
This study surveys leading European Union pharmaceutical companies using U.S. 
GAAP prior to using IFRS to identify first time IFRS adoption practices and choices for 
accounting policies under IFRS. The research tools include SEC EDGAR Company 
Search, Business Database: Financial Markets and Services, and Net Advantage. 
 Survey results are analyzed into three parts in this thesis. First, I looked at the four 
most commonly used IFRS 1 optional exemptions at transition date: IFRS 3R, business 
combinations, IAS 19, employee benefits, IAS 21, cumulative translation differences, and 
IFRS 2, share-based payments. Second, I analyzed the reconciliations of equity and net 
profit between U.S. GAAP and IFRS. I found that IFRS adoption results in lower net 
income and higher shareholders’ equity than U.S. GAAP for my sampled companies. By 
comparing the several financial ratios under U.S. GAAP and IFRS, I found that under 
IFRS, current ratio and return on assets increases, asset turnover tends to decrease and 
debt to equity ratio decreases. However, these results should be interpreted with caution 
because of the small sample used and the sample’s nationality (mostly Germany). Third, I 
analyzed accounting choices under IFRS. IFRS allows companies to choose from a 
number of alternative accounting treatments. All the surveyed companies made similar 
accounting choices. The common choices were to classify expenses by function, keep the 
cost method and straight-line depreciation method for property, plant, and equipment, and 
to continue using the indirect method to prepare cash flow statement as reported under 
U.S. GAAP. All these companies use either FIFO or average method for valuation of 
inventory since LIFO is forbade by IFRS. Six out of eight companies have the same 
revenue figures under U.S. GAAP and IFRS and all of these companies have different 
figures for R&D and intangible asset items even though seven out of eight kept expensing 
 R&D items. I also found it interesting that when converting to IFRS, R&D tends to 
decrease and intangible assets tend to increase even though development costs are not 
capitalized. Other accounting treatments vary and depend on the specific situation.  
The survey results could be valuable for U.S. companies because it provides 
benchmark information. It could also provide U.S. companies a cost-effective pathway in 
making their reporting choices in the near future.  
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 8. Tables 
Table 1: Company List 
Pharmaceutical 
company Transition Date Country 
Elan 1/1/2004 Ireland 
GPC Biotech 1/1/2004 Germany 
Shire 1/1/2004 England 
MediGene AG 1/1/2004 Germany 
Evotec 1/1/2004 Germany 
Schwarz Pharma AG 1/1/2004 Germany 
Sygnis Pharma AG  4/1/2004 Germany 
World of Medicine AG 1/1/2004 Germany 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2: List of IFRS 1 Optional Exemptions 
Item Standard No. Title 
1 IFRS 3R Business combinations  
2 IAS 16, 38, 40 Fair value or revaluation as deemed cost 
3 IAS 19 Employee benefits (on actuarial gains and losses) 
4 IAS 21 Cumulative (foreign) translation differences 
5 IAS 32 Compound financial instruments 
6 IAS 27, 28, 31 Assets and liabilities of subsidiaries, associates and joint 
ventures 
7 IAS 39 Designation of previously recognized financial instruments 
8 IFRS 2 Share-based payment transactions 
9 IFRS 4 Insurance contracts  
10 IFRIC 1 
Changes in existing decommissioning, restoration, and 
similar liabilities included in the cost of property, plant and 
equipment 
11 IFRIC 4 Leases  
12 IAS 39 Fair value measurement of financial assets and financial 
liabilities  
13 IFRIC 12 Service concession arrangements 
14 IAS 23 Borrowing costs  
15 IAS 27R Investments in subsidiaries, jointly controlled entities and 
associates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3: Summary of Elected Optional Exemption 
Item Standard Title Elan Shire MediGene Evotec Schwarz Sygnis World of Medicine 
1 IFRS 3R Business combinations I I I II I II I 
3 IAS 19 Employee benefits I N/A I N/A I N/A II 
4 IAS 21 Cumulative translation differences II I I II II I II 
8 IFRS 2 Share-based payment transactions I I I I I N/A N/A 
I: Not to retrospectively apply the standard before the date of transition 
II: Retrospectively apply the standard before the date of transition 
N/A: Not Applicable 
Item 3 can not be applied on Shire, Evotec and Sygnis since these three companies have used defined contribution plan. 
Item 8 can not be applied on Sygnis and World of Medicine since these two companies don’t have share-based payment transactions. 
 Exhibit 1: Schwarz: other comprehensive income (loss) from 2005 Annual 
Report page 89  
  
Currency Translation 
Differences 
Other Comprehensive Income 
(Loss) 
Status on 
1/1/2005 (61,829) (61,829) 
Change 60,968 60,968 
Status on 
31/12/2005 (861) (861) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 4 Summary of Currency Translation Difference  
  cumulative currency translation differences 
 1/1/2004 12/31/2004 12/31/2005 12/31/2006 12/31/2007 12/31/2008 
Elan (in million $) -12.2 -12.9 -15.6 -11.7 -11 -11 
Evotec (in thousands €) -40,046 -39,005 -35,856 -33,956 -42,827 -38,835 
Schwarz (in thousands €) -31,348 -61,829 -861 -51,577 -4,428 N/A 
World of Medicine (in thousands € ) 67 -106 -87 -8 -521 -267 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 5: Accounting Difference in Net Income (NI) 
NI-IFRS NI-USGP Difference Percentages Company in year 2004 (1) (2) (1)-(2) [(1)-(2)]/(1) 
Elan (millions $) -379.5 -394.7 15.2 4.00% 
GPCB 1 (2007 T€2 ) -73,595 -69,245 -4,350 -5.90% 
Shire (T$3) 96,509 269,007 -172,498 -179%4 
MediGene (T€) -12,666 -12,306 -360 -2.84% 
Evotec (T€) -77,812 -84,203 6,391 8.20% 
Schwarz (T€) -835 1,844 -2,679 -320%5 
Sygnis (T€) -12,945 -13,150 205 1.58% 
World of Medicine  
(T€) -7,922 -6,396 -1,526 19.26% 
Mean    -59.34% 
Median    -0.63% 
1. GPCB’s financial figures under both USGP and IFRS is found in 2007’s financial 
statements instead of 2004 
2. T€: figures in thousands of euros except for percentages  
3. T$: figures in thousands of dollars 
4. -179%*: the 2004 IFRS income statement of Shire presents much higher R&D (210,974) 
and selling general and administrative expenses (718,890) than those (196,265 and 516,645 
respectively) of USGP, leading to lower net income under IFRS than USGP. 
5. -320%*: the 2004 IFRS income statement of Schwarz presents much lower other income 
from investment (101T€) than that (17,890 T€) of USGP, leading to lower net income under 
IFRS than USGP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 6: Specific items and their proportions to the IFRS Net Income in 
reconciliation table 1 
Reconciliation item in Net 
income/companies Elan GPCB
3
 Shire4 MediGene Evotec Schwarz Sygnis World of Medicine 
Intangible assets 6%2        
Financial 
instruments/non-consolidated 17%        
Revenue recognition 12%        
Acquired product rights and 
finance charges write off 3%        
Share-based payments 4%        
Other 6%        
General and administrative 
expenses    3% 0.10%    
Interest income and 
expenditures    0.10% 0.03%    
Costs of revenue     0.20%    
Research and development 
expense     0.40%    
Amortization of intangible 
asset     0.06%    
Impairment of goodwill     14%    
Impairment of tangible asset     6%    
Net loss from equity 
investments     0.30%    
Deferred tax benefit     7% 62%   
Executive stock options 
programs      372%   
Inventories      160%   
Property, plant and 
equipment      14%   
Other non-current provisions      71%   
Employee benefits      99%   
Adjustment of severance 
provision       1.60%  
Deferred tax adjustment due 
to adjusted budget horizon        7% 
1. Reconciliation Table usually indicates how equity and net profit from U.S.GAAP get reconciled to IFRS  
2. The percentage is calculated by dividing the specific reconciliation item by company’s IFRS Net income. 
3. The reconciliation item of GPCB is not available.  
4. Shire only provides reconciliation between UK GAAP and IFRS instead of U.S GAAP and IFRS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 7: Accounting Difference in Stockholders Equity (SE) 
SE-IFRS SE-USGP Difference Percentages Company (1) (2) (1) - (2) [(1) - (2)]/(1) 
Elan (million $) 538 205 333 62.00% 
GPCB (2007 T€) 44,119 38,603 5,516 12.50% 
Shire (T$) 4,244,932 2,250,653 1,994,279 45.80% 
MediGene (T€) 29,249 29,220 29 0.10% 
Evotec (T€) 110,508 102,498 8010 7.20% 
Schwarz (T€) 528,211 528,797 -586 -0.10% 
Sygnis (T€) 23,538 23,593 -55 -0.23% 
World of Medicine 
(T€) 19,250 20,597 -1,347 -6.70% 
Mean    15.07% 
Median    3.65% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 8: Specific Items and their proportions to the IFRS SE in Reconciliation Table1 
Reconciliation item in 
equity/companies Elan GPCB
3
 Shire4 MediGene Evotec Schwarz Sygnis World of Medicine 
Intangible assets 45%2        
Financial 
instruments/non-consolidated 3%        
Revenue recognition 20%        
Other 0.20%        
Additional pain-in capital    0.40% 2%    
Accumulated deficit    4% 6%    
Net income recognized directly in 
equity    3%     
Reserve     0.50%    
Inventories      0.20%   
Property, plant and equipment      0.01%   
Restructuring provisions      0.10%   
Other non-current provisions      0.40%   
Employee benefits      0.80%   
Deferred tax      0.20%   
Currency translation differences      0.03%   
Minority interests      0.20%   
Adjustment of severance provision       0.20%  
Net income/loss carried forward        1% 
Net income/net loss        8% 
1. Reconciliation Table usually indicates how equity and net profit from U.S.GAAP get reconciled to IFRS  
2. The percentage is calculated by dividing the specific reconciliation item by company’s IFRS Net equity. 
3. The reconciliation item of GPCB is not available.  
4. Shire only provides reconciliation between UK GAAP and IFRS instead of U.S GAAP and IFRS. 
 Table 9: Summary of Major Items in Reconciliation Disclosures 
Companies Significant reconciliation items for NI and SE 
Elan Financial instruments, revenue recognition 
GPC Biotech No discussion 
 
Shire No discussion 
 
MediGene Accumulated deficit, net income recognized in equity (no 
explanation) 
Evotec Impairment of goodwill, impairment of tangible assets 
Schwarz  Employee benefits, inventory 
Sygnis  Adjustment of severance provision 
World Of Medicine  Deferred tax adjustment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 10: The effects of IFRS transition on financial ratios  
  IFRS Shire (2005 T $) Evotec (2004 T€) GPCB (2007 T€) Schwarz (2004 T€) 
    USGP IFRS USGP IFRS USGP IFRS USGP IFRS 
R&D Expenses Lower R&D  336,217 287,146 13,772 13,490 51,437 50,551 197,667 198,321 
NI or OI Higher profit or lower loss -410,843 -177,378 -84,203 -77,812 -69,245 -73,595 19291 OI 15030 OI 
Liquidity: Current Ratio 
=CA/CL   
Deferred 
Income Tax 
makes it lower  
1,312,222/965,421 
= 1.36  
1,245,217/968,940 
= 1.29 
44,949/20,886 
= 2.15   
44,869/21,512 
= 2.09  
69,114/17,603 
= 3.93  
69,114/17,726 
= 3.90 
522,115/328,526
= 1.59 
484,198/261,398
= 1.85 
Profitability Ratio Return on 
Assets=Net Income/Assets 
Depends Appear 
to be higher 
-410,843/2,798,240 
= -0.15  
-177,378/5,227,905 
= -0.03 
-84,203/138,534 
=- 0.61   
-77,812/146,544 
= -0.53 
-69,245/73,386 
= -94.49% 
-73,595/78,658 
= -93.56% 
19,291/994,460 
= 1.9% 
15,030/943,898 
= 1.6% 
Activity Ratio Asset 
turnover=Sales/Assets Lower 
1,599,316/2,798,240 
= 0.57 
1,599,316/5,227,905 
= 0.31 
72,730/138,534 
= 0.52 
72,730/146,544 
= 0.50 
18,315/73,386 
= 0.25  
22,252/112,523 
= 0.20 
946,647/994,460
= 0.95 
946,647/943,898
= 1.002 
Leverage Ratio   
Debt/Equity Lower 
1,008,974/1,789,266 
= 0.56 
1,144,772/4,083,133 
= 0.28 
36,524/102,010 
= 0.36 
36,036/110,508 
= 0.33 
34,783/38,603 
= 0.90 
34,539/44,119 
= 0.78 
465,663/528,797
= 0.88 
415,687/528,211
= 0.79 
Note: USGP: U.S. GAAP 
Given the availability of some important figures, some data are from different year than 2004. 
 
 
 
 Table 11: Accounting choices   
    Elan GPCB Shire MediGene Evotec Schwarz Sygnis WM 
IAS 1 Presentation of Financial Statements                 
  Expenses Classification 1-Functional 2-Nature 1 1 1 1 1 1 1 1 
IAS 7 Cash Flow Statement         
  Method: 1-Indirect 2-Direct 1 1 1 1 1 1 1 1 
  Interest Expense:          
  1-Operating Activity 2-Financing Activity 1 1 2 nd 1 nd 1 1 
  Interest Income:          
  1-Operating Activity 2-Investing Activity 1 1 2 nd nd nd 1 nd 
  Dividend Income:          
  1-Operating Activity 2-Investing Activity  nd nd nd nd nd nd nd nd 
IAS 2 Valuation of Inventories (Method)         
  US-GAAP method 1-FIFO 2-Average 3-LIFO nd nm nd nd 2 2,3 nd 2 
  IFRS: 1-FIFO 2-Average 1 nm 1 nd 2 2 nd 2 
IAS 16 Property, Plant And Equipment           
  Valuation Method: 1-Cost 2: Revaluation 1 1 1 1 1 1 1 1 
Depreciation Method: 1-Straight Line            
2-Accelerated Declining 3-SYD 1 1 1 1 1 1 1 1 
IAS 19 Employee Benefits         
  Actuarial gains/losses: 1-Immediate Recognition 2-Corridor  1 N/A N/A 1 N/A 2 nd nd 
Foreign Exchange Rates         
1-Period end closing rate 2 Average          IAS 21 
3-Spot rate of transaction date         
  Balance Sheet: 1 1 1 1 1 1 1 1 
  Income Statement 1 3 1 1 1 1 1 1 
  Statement of Cash Flow nd nd nd nd nd nd nd nd 
IFRS 2 Share-Based Payments/Stock Options         
  Black-Scholes option-pricing model  Y Y Y N nd nd nd nd 
  Other (be specific)       Binomial         
nd: no discussion provided   N/A: not applicable 
nm: The company specified the item is not material 
 Table 12: Summary of Accounting Difference in Revenue Recognition 
Pharmaceutical 
companies 
2004 revenue under 
IFRS (1) 
2004 revenue under 
USGP(2) [(1)-(2)]/(1) 
Elan (millions $) 367 481.7 -31% 
GPCB (2007 T€) 18,022 18,315 -1.60% 
Shire (T$) 1,363,207 1,363,207 0 
MediGene (T€) 13,138 13,138 0 
Evotec (T€) 72,730 72,730 0 
Schwarz (T€) 946,647 946,647 0 
Sygnis (T€) nd nd nd 
World of Medicine 
(T€) 30,811 30,811 0 
All these data are from 2004 financial statements except GPCB used data from 2007 
 
 
 
 
 
 
 
 
 
 
 
  
Table 13: Accounting Difference in R & D and Intangible Asset (IA)  
R&D-IFRS R&D-USGP Difference Percentages IA-IFRS IA-USGP Difference Percentages 
Company 
(1) (2) (1)-(2) [(1)-(2)]/(1) (1) (2) (1)-(2) [(1)-(2)]/(1) 
Elan (million $) 262.6 257.3 5.3 2% 1013 753.7 259.3 26% 
GPCB (2007 T€) 50,551 51,437 -886 -2% 6105 164 5,941 97% 
Shire (2005*T$) 287,146 336,217 -49,071 -17% 1,394,677 729,304 665,373 48% 
MediGene (T €) 15,627 14,701 926 6% 7,020 7,020 0 0% 
Evotec (T€) 13,490 13,772 -282 -2% 7,963 7,507 456 6% 
Schwarz (T€) 197,667 198,321 -654 -0.3% 199,361 196,189 3,172 2% 
Sygnis (T€) N/A N/A N/A N/A N/A N/A N/A N/A 
World of Medicine (T€) 3,955,455 3,955,455 0 0% 1,858,779 1,858,779 0 0% 
Mean    -3%    25% 
Median    -0.3%    6% 
Note: All these data are from 2004 except for Shire and GPCB  
*. relative figures from 2005 are used given the availability of the data under both U.S.GAAP and IFRS 
 
 
 
 
 
 
 
 
 
 
 
 
 9. Appendix: 
This Appendix contains five parts as follows: 
9.1－company background 
9.2－excerpts on key items from both U.S. GAAP and IFRS 
9.3－excerpts on exemptions from Shire, Elan and MediGene  
9.4－excerpts on reconciliation from Elan 
 
9.1 Company background 
 
Evotec 
Evotec AG is a biotechnology group dedicated to the discovery and development of novel 
small molecule drugs through both its own discovery programs and through contract 
research partnerships. It was founded on 8th December 1993. The geographical spread of 
revenues for the Group continues to be diverse. Europe continues to be the largest market 
with 51% of total revenues (2004: 46%), and the US market being second at 37% (2004: 
42%). The Group’s overall gross margin for 2005 was 36.3% (2004: 34.1%) with cost of 
revenues amounting to € 50.8 m (2004: € 47.9 m). This improvement comes as a result of 
a program of cost and efficiency improvements across all divisions together with 
changing market demands which have improved the revenue mix. While the US Dollar 
continues to be weak and therefore affects the Company’s pricing and gross margin 
versus competitors with US based operations, the average US Dollar exchange rate was 
the same in 2005 as in 2004, and therefore currency effects have had less of an impact on 
the year on year comparisons. In total, currency contributed 0.6% points to the margin 
improvement. The Company’s consolidated financial statements of 31 December 2005 
are prepared in accordance with International Financial Reporting Standards (IFRS). 
 
GPC Biotech 
GPC Biotech is a publicly traded biopharmaceutical company focused on discovering and 
developing anticancer drugs and is incorporated in Germany. Its wholly owned U.S. 
subsidiary is located in Princeton, New Jersey. The consolidated financial statements of 
GPC Biotech AG and its subsidiary have been prepared in accordance with IFRS. Year 
2005 is the first year that GPC Biotech converted to IFRS from U.S.GAAP; however it 
did not provide IFRS financial statement until 2007, which does not provide first time 
 adoption practice. The year 2007 turned out to be the most difficult year in the history of 
GPC Biotech. In February, the company completed a New Drug Application Submission 
for Satraplatin. Unfortunately, in late October 2007, the company announced that 
Satraplatin did not demonstrate an improvement in overall survival in the total patient 
population enrolled in the SPARC trial. 
 
Shire 
Shire Group develops and market products for specialty physicians. The Group focuses 
on four therapeutic areas: central nervous system, gastro-intestinal, human genetic 
therapies and general products. This is the first year that the Company has presented its 
financial statement under IFRS.  
Substantially all of the Company’s revenues, expenditures, operating profits or losses and 
net assets are attributable to the Research and Development (R&D), manufacture, sale 
and distribution of pharmaceutical products within two operating segments: 
Pharmaceutical Products and Royalties. 83% (2004: 82%) of total revenues are derived 
from product sales, 15% of total revenues are derived from royalties (2004: 17%). All 
royalty income falls within the Royalties segment. For the year to December 31, 2005, the 
Company’s total revenues increased by 17% to $1,599.3 million, compared to $1,363.2 
million in 2004. Net loss for the year to December 31, 2005 was $177.4 million compared 
to net income of $96.5 million in 2004. The results for 2005 include a $527.0 million 
impairment of the goodwill that arose on the acquisition of BioChem Pharma Inc. (2004: 
an impairment of $132.6 million was recorded).  
 
MediGene 
MediGene Group was founded in 1994 in Germany. The purpose of the Group is research, 
development and commercialization of, in particular, technologies applied in molecular 
biology processes and products in the field of drugs, pharmaceutical substances. Year 
2005 is the first year that the Company has presented its financial statement under IFRS. 
MediGene’s revenue increased by 50% in 2005. The increase results particularly from its 
first drug on the market, Eligard, for the treatment of prostate cancer. In June 2005, 
MedeGene was honored with the ARC award- The World’s Best Annual Report for its 
annual report in 2004. 
 
 
 Elan 
Elan Corporation is a neuroscience-based biotechnology company headquartered in 
Dublin, Ireland. It was incorporated as a private limited company in Ireland in December 
1969 and became a public limited company in January 1984. Its principal research and 
development, manufacturing and marketing facilities are located in Ireland, the United 
States (U.S.) and the United Kingdom (U.K.). Its business is organized into two business 
units: Biopharmaceuticals and EDT. Biopharmaceuticals engages in research, 
development and commercial activities and includes our activities in the areas of 
autoimmune diseases, neurodegenerative diseases and our specialty business group. EDT 
focuses on product development, scale-up and manufacturing to address drug 
optimization challenges of the pharmaceutical industry. Prior to the 2004 fiscal year, its 
Consolidated Financial Statements had adopted Irish GAAP. Beginning with 2004 fiscal 
year, it has adopted U.S. GAAP as the basis for the preparation of Consolidated Financial 
Statements. Accordingly, it’s Consolidated Financial Statements on this Form 20-F are 
prepared on the basis of U.S. GAAP for all periods presented. It also prepared separate 
Consolidated Financial Statements in accordance with IFRS since the year ended 
December 31, 2005. Financial Statements are presented in U.S. dollars rounded to the 
nearest million, being the functional currency of the parent company and the majority of 
the group companies. It has incurred significant losses during the last three fiscal years 
and anticipates continuing losses for the foreseeable future. 
 
Schwarz Pharma 
The SCHWARZ PHARMA Group is a multinational pharmaceutical enterprise supplying 
a broad and diversified range of pharmaceutical products and services, with activities in 
research, development, marketing approval, manufacturing, and marketing. Its research 
activities are chiefly concentrated in two of its group companies, one in Germany and one 
in the USA, while its production sites are located in the USA, Ireland, Germany, and 
Poland. It also operates a China-based joint-venture production company in Zhuhai. The 
group’s distributors are spread out throughout the USA, Europe, and Asia. 2004 was 
particularly marked by advances in clinical development. One highlight certainly was 
submitting the applications for market approval with the U.S. and European regulatory 
authorities for Neupro® (rotigotine transdermal system). The consolidated financial 
statements have been prepared in accordance with IFRS since 2005 as required by 
European Union. In fiscal year 2005, the SCHWARZ PHARMA Group achieved sales of 
 €990.6 million, marking a 4.6% increase over the previous year. The acquisition of the 
entire rotigotine rights in July 2005 led to an operating result of €–17.0 million, after 
€15.8 million in the previous year, and a net result of €–54.1 million (€–0.8 million). 
 
Sygnis Pharma 
It was incorporated in Germany in March 1997. The company originally offered drug 
discovery and knowledge management IT solutions and developed information 
management software and data integration to improve R&D performance in the life 
science industry.  On March 24, 2005, the enlargement of the company’s business 
purpose was approved. It now also includes the acquisition, holding, administration and 
the sale of investments, especially in the life science and IT market. At the end of fiscal 
year 2005, it sold its core business, bioinformatics unit, to BioWisdom Ltd. As a result of 
the sale and drastic reduction of workforce, it has also implemented the downsizing of the 
management board. Its consolidated financial statements were prepared in accordance 
with U.S.GAAP up to and include 2005. As a gear to capital market,  it changed its 
accounting in full to IFRS as of April 1 2005, applying IFRS 1 , “First time adoption”  
 
World of Medicine 
W.O.M.AG is a supplier of technical equipment for Minimally Invasive Surgery (MIS), 
and develops, manufactures and distributes primarily insufflators, pump systems, cameras, 
light sources and video documentation systems for MIS, as well as the accessories and 
disposable supplies necessary for devices application. It has been the global market leader 
in this area for more than 30 years. The aforementioned products from W.O.M Group are 
distributed worldwide. The subsidiary W.O.M USA Inc. is responsible for marketing and 
sales in North America. The Germen subsidiary exclusively supplies research and 
development services for the Group. The consolidated financial statements have been 
prepared in accordance with IFRS since 2005 as required by European Union. In 2005, it 
minimized dependency on exchange rates in the core business by shifting purchasing 
volume to U.S. dollar territory. Its consolidated revenue declined by about 6%. This 
decline is attributed to the delayed launch of the new generation of digital camera and the 
challenging market environment in Europe. 
 
 
 9.2 Excerpts on key items from both U.S. GAAP and IFRS: 
 
Elan R&D (U.S. GAAP)–from 2005 U.S. GAAP Annual Report page15 
R&D costs are expensed as incurred. Acquired in process research and development 
arising on business combinations is expensed on acquisition. Costs to acquire intellectual 
property, product rights and other similar intangible assets are capitalized and amortized 
on a straight-line basis over the estimated useful life of the asset. The method of 
amortization chosen best reflects the manner in which individual intangible assets are 
consumed. 
Elan R&D (IFRS) –from 2005 IFRS Annual Report page85 
Expenditure on research activities undertaken with the prospect of gaining new scientific 
or technical knowledge and understanding is expensed as incurred. Expenditure on 
development activities, whereby research findings are applied to a plan or design for the 
production of new or substantially improved products and processes, is expensed when 
incurred, unless the criteria for recognition of an internally generated intangible are met. 
Regulatory and other uncertainties generally mean that such criteria are not met. To date, 
we have not had any development expenditures that have met the criteria for recognition 
of an internally generated intangible asset. 
GPCB R&D (U.S. GAAP)–from 2005 U.S. GAAP Annual Report page46 
Research and development (R&D) expenses include salaries, benefits, and other 
headcount related costs; clinical trial and related clinical manufacturing costs; contract 
and other outside service fees; employee stock-based compensation expense; and 
facilities and overhead costs. R&D expenses consist of independent R&D costs and costs 
associated with collaborative R&D and in-licensing arrangements. In addition, we 
acquire R&D services from other companies and fund research institutions under 
agreements which we can generally terminate at will. 
GPCB R&D (IFRS)–from GPCB 2005 IFRS Annual Report page40 
In accordance with IAS38, research costs, which are defined as costs of original and 
planned research performed to gain new scientific or technical knowledge and 
understanding, are expensed as incurred. Development costs are defined as costs 
incurred to achieve technical and commercial feasibility. Since regulatory and other 
uncertainties inherent in the development of the company’s new products are so high that 
the requirements set out in IAS38 are not met, these internal development costs are not 
capitalized, but expensed as incurred. 
 GPCB 
Similar part of Revenue Recognition under U.S. GAAP and IFRS–from 2007 IFRS 
Annual Report p46 and 2007 U.S. GAAP Annual Report page46 
Licensing Arrangements 
The Company generally receives non-refundable upfront fees upon signing of a licensing 
agreement. These fees generally include licensing fees, technology access fees and 
initiation fees. All non-refundable upfront fees received or to be received under these 
arrangements are recognized when SAB 104 revenue recognition criteria are met, ratably 
over the term of the agreements, as this is the period over which the license is granted or 
the Company is substantially and continually involved. 
Co-Development Arrangements 
Revenue recognized from partners in co-development arrangements is generally based on 
a fixed-percentage of agreed upon research, development and commercialization costs 
incurred by the Company. Revenue from these co-development arrangements are 
recognized on a gross basis as collaboration revenue in the consolidated statement of 
operations as the related costs are incurred. If payments are received prior to the activity 
having been performed, these amounts are deferred and recognized in future periods 
when the co-development costs are incurred. 
Milestone Payments 
Milestone payments are recognized as revenue when the performance obligations, as 
defined in the contracts, are achieved. Performance obligations typically consist of 
significant milestones in the life cycle of the related technology or product candidate, 
such as initiation of clinical trials, filing for approval with regulatory agencies and 
approvals by regulatory agencies. These milestone payments are generally tied to a 
specific performance condition and are recognized in full when the performance 
obligation is met. The reaching of a milestone is evidenced by a milestone confirmation 
letter that is signed and dated by both parties. In the absence of such milestone 
confirmation, no milestone revenue is recognized, unless there is other persuasive 
evidence that the milestone event has been reached and the milestone fee has been 
earned. 
Different part of Revenue Recognition: 
GPCB Revenue (U.S. GAAP)–from 2007 U.S. GAAP Annual Report page46 
Grant revenues from governmental agencies for the support of specific research and 
development projects are recorded as revenue to the extent the related expenses have been 
 incurred and billed in accordance with the terms of the grant. 
GPCB Revenue (IFRS)–from 2007 IFRS Annual Report page48 
Grants from governmental agencies for the support of specific research and development 
projects are recorded as other income to the extent the related expenses have been 
incurred and billed in accordance with the terms of the grant. 
 
9.3 Excerpts on exemptions from Shire, Elan and MediGene: 
Shire–from 2005 IFRS Annual Report page102 
40 Explanation of transition to IFRS 
This is the first year that the Company has presented its financial statement under IFRS. 
The following disclosures are required in the year of transition. The last financial 
statements under UK GAAP were for the year ended December 31, 2004 and the date of 
transition to IFRS was therefore January 1, 2004. 
Exemptions from full retrospective application -elected by the Group 
The Group has elected to apply the following optional exemptions from full retrospective 
application. 
Business combinations exemption 
The Group has applied the business combination exemption in IFRS 1. It has not restated 
business combinations that took place prior to the January 1, 2004 transition date in 
accordance with IFRS 3, Business Combinations. 
Cumulative translation differences exemption 
The Group has elected to set the previously accumulated cumulative translation 
differences arising on the translation and consolidation of results of foreign operations 
and balance sheets denominated in foreign currencies to zero at January 1, 2004. This 
exemption has been applied to all subsidiaries in accordance with IFRS 1. 
Exemption from restatement of comparatives for IAS 32 and IAS 39 
The Group has elected to apply this exemption. It applies UK GAAP rules to derivatives, 
financial assets and financial liabilities and to hedging relationships for the 2004 
comparative information. The adjustments required for differences between UK GAAP 
and IAS 32 and IAS 39 are determined and recognized at January 1, 2005. 
Designation of financial assets and financial liabilities exemption 
The Group reclassified various equity investments as available-for-sale investments. The 
adjustments relating to IAS 32 and IAS 39 are required and determined at the opening 
balance sheet date of January 1, 2005 -the IAS 32 and IAS 39 transition date. 
 Share-based payment transaction exemption 
The Group has elected to apply the share-based payment exemption. It applied IFRS 2 
from January 1, 2004 to those options that were issued after November 7, 2002 but that 
have not vested by January 1, 2005. 
Fair value measurement of financial assets or liabilities at initial recognition 
The Group has applied the exemption offered by the revision of IAS 39 on the initial 
recognition of the financial instruments measured at fair value through the income 
statement where there is no active market. 
Elan –from 2005 IFRS Annual Report page147 
Exemptions under IFRS 1 
In accordance with IFRS 1, which establishes the framework for transition to IFRS by a 
first-time adopter, we elected to avail ourselves of a number of specified exemptions from 
the general principle of retrospective restatement as follows: 
(i) Business combinations: 
Business combinations undertaken prior to the transition date of 1 January 2004 have not 
been subject to restatement and accordingly, goodwill at the transition date is carried 
forward at its net book value and is subject to annual impairment testing in accordance 
with IAS 36, “Impairment of Assets” 
(ii) Employee benefits: 
The corridor method has been applied retrospectively and the cumulative actuarial gains 
and losses from the date of inception of our defined benefit pension plans have been split 
into a recognized portion and an unrecognized portion and the recognized portion has 
been adjusted against retained loss in the opening balance sheet. 
(iii) Share-based payments: 
IFRS 2 has been applied retrospectively to those options that were issued after 7 
November 2002 and had not vested by 1 January 2005. 
(iv) Financial instruments:  
We have adopted IAS 32 and IAS 39 from 1 January 2005, with no restatement of 
comparative information. Therefore, financial instruments in the comparative 2004 
period continue to be recorded on an Irish GAAP basis. With effect from 1 January 2005, 
we reclassified various financial instruments as available-for-sale investments and as 
derivatives at fair value through the income statement. 
 
 
 MediGene – from 2005 Annual Report page55 
(2) Relief options in IFRS 1 as per the transition date January 1, 2004 are being used 
as follows: 
Business Combinations: 
MediGene AG acquired a company in 2001. MediGene’s management decided that it 
would make use of the relief option for corporate mergers provided for under IFRS 1 and 
that, consequently, the previous accounting principles for corporate mergers carried out 
before the transition date (January 1, 2004) would not be adapted to the new principles. 
Foreign currency translation: 
IFRS 1 allows companies to apply the standard IAS 21 (the effects of changes in Foreign 
Exchange rates) prospectively. This means that it is assumed that all of the accumulated 
currency exchange gains and losses reported according to US-GAAP before the transition 
date are valued at zero as at the date of transition to IFRS. And that currency exchange 
differences which arise after the transition date must be reported separately in the 
balance sheet for each foreign subsidiary. The differences that emerge are set at zero at 
the date of transition from US-GAAP to IFRS in the item “Net income/expenses recorded 
directly in equity” and the retained earnings are reduced accordingly. The retained 
earnings are reported in the balance sheet under the item “Accumulated Deficit”. 
Compound Financial Instruments: 
A compound financial instrument is divided into an equity and borrowings component 
only if the borrowings component still exists as at the transition date (January 1, 2004). 
These compound financial instruments are portrayed in accordance with IAS32 or IAS 39. 
The equity component is produced by the difference between the issue proceeds and the 
fair value of the future payment obligations (borrowings component). 
Share-based compensation: 
Share-based instruments, such as options and convertible bonds issued to employees are 
reported in the balance sheet in accordance with IFRS 2. Under this regulation, the 
reporting of share-based instruments that were issued before November 7, 2002 is 
waived. 
No further options in addition to the above are used for the transition from US-GAAP to 
the new accounting standard. 
Mandatory exemptions 
The application of the mandatory exemptions in IFRS 1 did not give rise to any 
adjustments. 
  
Schwarz – from 2005 Annual Report page39 
The following exemptions from retrospective adjustment were elected pursuant to IFRS 1: 
Business combinations (IFRS 1.15): Goodwill from historic acquisitions of companies 
measured and carried forward under US GAAP are carried forward in the opening 
balance sheet. The balance sheet values as per 1 January 2004 were tested for 
impairment pursuant to IAS 36. 
Employee benefits (IFRS 1.20): All actuarial gains and losses exceeding the 10% 
corridor of the higher value of the present value of the pension liabilities and the plan 
assets as per 1 January 2004 were fully set off against employee benefits, leaving no 
actuarial gains and losses unrecognized in shareholders’ equity. 
Share-based payment transactions (IFRS 1.25B and 1.25C): Stock option programs 
granted prior to 7 November 2002, and those granted after 7 November 2002 that were 
already fully exercisable at the time of the opening balance sheet, were not taken into 
consideration in preparing the opening balance sheet. They will not affect the net result 
posted in the consolidated financial statements of the SCHWARZ PHARMA Group in 
future. Hence, specifically the first, second, and third trances of the Executive Stock 
Option Program 2000 are not taken into account in the group’s 
IAS/IFRS consolidated financial statements. However, the effects of the Executive Stock 
Option Program 2003 (first and second trances) were and will in future be expensed in 
the consolidated financial statements. 
 
9.4 Excerpts on reconciliation –from Elan 2005 IFRS Annual Report page152  
Reconciliation from IFRS to U.S. GAAP 
The following is reconciliation to net loss and shareholders equity calculated in accordance with U.S. 
GAAP: 
Net income/ (loss) for the years ended: 
 31 December 31 December 
 2005 2004 
 $m $m 
Net income/(loss) as stated under IFRS 612.3 (379.5) 
Adjustments to conform to U.S. GAAP:   
(a) Intangible assets 64.3 21.8 
(b) Financial instruments/non-consolidated subsidiaries 8.1 (63.2) 
(c) Revenue recognition 50.8 46.2 
(d) Convertible notes—fair value on conversion option (1,136.1) — 
(d) Convertible notes—net charge on debt retirement (31.6) — 
 (d) Convertible notes—accretion of discount 12.4 — 
(e) Acquired product rights and finance charges write off — (12.0) 
(f) Share-based payments 36.6 15.1 
Other (0.4) (23.1) 
Net loss as stated under U.S. GAAP (383.6) (394.7) 
 
Shareholders’ equity 
 
 31 December   31 December
 
 2005   2004  
  
 $m   $m  
 Shareholders’ equity as stated under IFRS    308.4   538.0  
 Adjustments to conform to U.S. GAAP:       
 (a) Intangible assets    (177.3)   (241.6)  
 (b) Financial instruments/non-consolidated subsidiaries    (1.4)   14.7  
 (c) Revenue recognition    (56.4)   (107.2)  
 (d) Convertible notes    (46.4)   —  
 Other    (10.0)   1.1  
 Shareholders’ equity as stated under U.S. GAAP    16.9   205.0  
 
The principal differences between IFRS as adopted in the EU and U.S. GAAP, as they 
apply to our financial statements, are as follows: 
a. Intangible assets 
The carrying value of our intangible assets is higher under IFRS than under U.S. GAAP 
because of differences in our historical Irish GAAP accounting for business combinations 
which have carried into our IFRS financial statements as part of the transitional 
arrangements. This in turn gives rise to a higher amortization charge under IFRS than 
under U.S. GAAP. Additionally, higher carrying values under IFRS will result in higher 
intangible impairment charges if the fair value of the related intangibles declines 
post-acquisition. 
The principal reason for a higher carrying value of intangibles under IFRS is that under 
U.S. GAAP, the fair value of acquired IPR&D is expensed upon acquisition, whereas 
under Irish GAAP as carried into IFRS these amounts are capitalized as acquired IPR&D. 
Additionally, under U.S. GAAP, our acquisition of Dura was accounted for under the 
pooling-of-interests method, whereas under Irish GAAP and now IFRS this transaction 
was accounted for using the purchase method. As a result, under U.S. GAAP, the assets 
and liabilities of Dura were recorded at their historical carrying amounts and no goodwill 
arose from the merger of Dura and Elan, whereas under IFRS the assets and liabilities of 
Dura were recorded based on their fair values at the date of acquisition, and the excess of 
the purchase price over the fair value of assets acquired was allocated to goodwill. Also, a 
 number of differences arise in the manner in which goodwill was previously written off 
when businesses were sold under Irish GAAP and U.S. GAAP. As we did not restate our 
historical business combinations in accordance with IFRS 3, “Business Combinations”, as 
permitted by IFRS 1, these differences remain in effect between U.S. GAAP and IFRS. 
b. Financial instruments/non-consolidated subsidiaries 
Effective 1 January 2005  
We have adopted IAS 32 and IAS 39 effective 1 January 2005, which eliminates many of 
the investment related differences with our U.S. GAAP results. The principal remaining 
differences from 2005 onwards relate to the different carrying values for some of our 
investments under IFRS as compared to U.S GAAP. The definition of a derivative 
instrument under U.S. GAAP is similar to the IFRS definition with the result that the 
number of derivatives recorded at fair value through the income statement will be similar 
for both GAAPs. However, under U.S. GAAP, certain non-derivative investments, 
principally equity investments in private entities, are not marked-to-market through the 
balance sheet, whereas all non-derivative investments are marked-to-market through the 
balance sheet under IFRS with fair value changes taken through the fair value reserve.  
Prior to 1 January 2005 
Prior to 1 January 2005, our investments and derivatives were accounted for on an Irish 
GAAP basis, which resulted in a significant number of differences from U.S. GAAP. 
These are detailed below. Derivative instruments were marked-to-market through the 
income statement under both Irish GAAP and U.S. GAAP. However, 
The definition of a derivative instrument is significantly broader under U.S. GAAP than 
under Irish GAAP, with the result that more derivatives were marked-to-market through 
the income statement under U.S. GAAP than under Irish GAAP. Additionally, under U.S. 
GAAP, quoted common stock and certain debt instruments are marked-to-market on the 
balance sheet, but were not marked-to-market under Irish GAAP, and, consequently, 
shareholders’ equity differences arose. These differences will remain in effect as the 
carrying basis of certain investments under IFRS is derived from the Irish GAAP basis. 
Under Irish GAAP, when a convertible instrument is exercised and converted into 
common shares of the issuer, the common shares acquired as a result are recorded at their 
fair value on the date of conversion, with any excess over the carrying value of the 
convertible instrument recorded as a gain. Under U.S. GAAP, no gain is recorded upon 
conversion. As a result, there is a different historic cost basis for converted investments. 
Under IFRS, EPIL and EPIL II have been consolidated as subsidiaries of Elan, with the 
 loan notes issued by each entity being recorded as a liability and the related interest 
charges expensed through the income statement. Under U.S. GAAP, both entities were no 
consolidated subsidiaries through the date of repayment of their loan notes (March 2001 
and June 2004, respectively), as we had effected a true legal sale of a portfolio of 
investments to each entity and had not retained control over the transferred assets. 
Accordingly, the transfer of investments to each entity was treated as a sale of the assets 
at fair value under U.S. GAAP, and the related loan notes were not included as a liability. 
As a consequence, we did not record an expense for the related interest charges under U.S. 
GAAP. In addition, the timing and amount of charges related to impairments of the 
investments transferred to these entities differed under IFRS and U.S. GAAP, since under 
IFRS each investment was assessed for impairment individually at each balance sheet 
date, whereas under U.S. GAAP we recorded provisions under our guarantee agreements 
with the note holders based upon the difference at each balance sheet date between the 
fair value of the total assets of each entity and its total liabilities. 
c. Revenue recognition 
There are different rules under IFRS and U.S. GAAP in relation to the recognition of 
revenue arising under contracts which include multiple arrangements such as the sale of a 
product and related R&D or manufacturing arrangements. Although the revenue 
recognized will be the same under both IFRS and U.S. GAAP over the life of the contract, 
the different requirements can result in differences in the timing of revenue recognition. 
 
d .Convertible notes 
Effective 1 January 2005 
We have adopted IAS 32 and IAS 39 effective 1 January 2005, with no restatement of 
comparative information in prior periods. With the adoption of IAS 32 and IAS 39, the 
6.5% Convertible Notes are analyzed into a debt component and a separate embedded 
conversion option component. Under IFRS, prior to 28 October 2005, the conversion 
option in the 6.5% Convertible Notes was classified as a derivative within liabilities and 
fair valued through the income statement at each reporting period. The finance cost for 
the 6.5% Convertible Notes also includes an amortization charge for the discount between 
the initial fair value of the debt component of the 6.5% Convertible Notes and the 
proceeds received on issue. This discount under IFRS is determined on the issue date 
using a market interest rate for an equivalent non-convertible note, and is amortized along 
with issuance costs up to the maturity of the notes using the effective interest rate method, 
 such that the discounted carrying value of the debt will accrete to the principal amount 
over the period to the maturity date. This initial discount, which reflects the initial fair 
value of the conversion option, amounted to $128.7 million for the issue as a whole, of 
which $71.7 million, approximately 55%, related to the remaining principal amount of 
$254.0 million outstanding at 31 December 2005. Of this $71.7 million, an amount of 
$46.4 million remains unamortized at 31 December 2005. 
 On 28 October 2005, we removed the cash settlement feature from the Convertible 
Notes and as a result, the value of the remaining conversion option is fixed as of 28 
October 2005 at $91.8 million. It will not be subsequently remeasured after this date, and 
has been transferred from liabilities to shareholders equity, being the equity portion of a 
compound financial instrument. This $91.8 million increase in shareholders equity 
represents the initial fair value of $71.1 million of the conversion option (initial fair value 
discount on the debt) on the remaining $254.0 million of principal amount of the 6.5% 
Convertible Notes, plus the increasing of shareholders equity, upon the removal of the 
cash settlement feature, for the net cumulative mark-to-market loss of $20.7 million on 
the remaining principal amount (that had previously been expensed to shareholders 
equity). As described above, the $71.1 million is being amortized to interest expense over 
the period to the maturity date using the effective interest rate method. The effective 
interest rate of the 6.5% Convertible Notes is 15.9%. Of this $71.1 million, $46.4 million 
remains unamortized at 31 December 2005 
Under U.S. GAAP, there is no separate recognition of the conversion option, as it is 
deemed to be clearly and closely related to the debt instrument. As a result, there is no fair 
value movement on the U.S. GAAP income statement, nor an additional finance charge 
for the discount arising on separation of the instrument. Timing differences may also arise 
on net gains/(charges) on debt retirements, since under U.S. GAAP such gains/(charges) 
are recorded only as such transactions occur, whereas the requirement under IFRS to fair 
value the conversion option during each reporting period means that such gains/(charges) 
may have been partially recorded in prior period(s). The difference in shareholders equity 
of $46.4 million between U.S. GAAP and IFRS at 31 December 2005 represents the 
remaining unamortized initial fair value discount.  
This difference will decline over time to $Nil at maturity as this discount is amortized to 
interest expense under IFRS using the effective interest rate method. 
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 Prior to 1 January 2005 the convertible debt was accounted for under Irish GAAP on an 
amortized cost basis until extinguished on conversion or maturity. Therefore, there was no 
difference in the accounting treatment under Irish GAAP and U.S. GAAP. 
e. Acquired product rights and finance charges 
Under IFRS, contingent and potential product payments which are likely to be made in 
the future are recognized as a liability on a time discounted basis, with a corresponding 
finance charge being expensed annually. The contingent liabilities are released if the 
related assets are sold. Under U.S. GAAP, such contingent payments are not recognized 
in the financial statements until the related contingencies are resolved. 
f. Share-based payments 
IFRS requires that the fair value of share-based payments is expensed to the income 
statement over the period the related services are received, together with a corresponding 
increase in equity. There is no corresponding charge for share-based payments under U.S. 
GAAP for the periods presented. We will implement U.S. GAAPs Statement of Financial 
Accounting Standards (SFAS) No.123R, Share-Based Payment-An Amendment of FASB 
Statements No. 123 and 95, effective 1 January 2006. This standard will require us to 
expense the fair value of share-based payments, rather than using the intrinsic value 
method as previously allowed. Therefore, from 1 January 2006, we will record a similar 
share-based compensation expense under both IFRS and U.S. GAAP. 
g. Discontinued operations 
Under IFRS, a discontinued operation is a component of a company that either has been 
disposed of or is classified as held for sale and (i) represents a separate major line of 
business or geographical area of operations, (ii) is part of a single coordinated plan to 
dispose of a separate major line of business or geographical area of operations, or (iii) is a 
subsidiary acquired exclusively with a view to resale. Under U.S. GAAP, a discontinued 
operation is a component of an entity whose operations and cash flows have been or will 
be eliminated from the ongoing operations of the entity and the entity will not have any 
significant continuing involvement in the operations of the component after its disposal. 
As the criteria for the determination of discontinued operations are different under IFRS 
and U.S. GAAP, the products and businesses treated as discontinued operations differ 
under each. There are no reconciling differences to total net income/(loss) or shareholders 
equity between IFRS and U.S. GAAP related to discontinued operations. However, the 
split of net income/(loss) between continuing operations and discontinued operations 
differs under both GAAPs. 
 h. Held for sale assets 
A presentation difference arises between IFRS and U.S. GAAP on assets classified as 
held for sale. Under IFRS, comparatives are not restated to reflect the classification as 
held for sale at a reporting date, whereas under U.S. GAAP comparatives are restated to 
reflect current held for sale classifications. 
